DuPont Nutrition launches Bonlacta, an enzyme for lactose-free milk
Bonlacta is designed for high-temperature, short-time processing enabling lactose-free milk to become a mainstream reality for North American producers
Photo © iStockphoto.com/ ValentynVolkov
DuPont Nutrition & Biosciences (New Century, KN) launched Bonlacta enzyme, enabling process optimization and cost reduction for lactose-free products in North America. The new enzyme is fast acting under refrigeration conditions and can withstand high temperatures for faster lactose hydrolysis targets. Because of its thermal properties, it’s optimal for flash pasteurization or high-temperature short-time (HTST) processing for fluid milk and milk-derived products.
“The demand for lactose-free milk is growing rapidly across North America and we see Bonlacta as critical to meeting that need,” said Clementina Dellomonaco, global product line manager, dairy enzymes at DuPont Nutrition & Biosciences, in a press release. “We know the exceptional performance of Bonlacta can create cost-competitive products, allowing more dairy producers to go mainstream with lactose-free milk.”
Bonlacta offers a clean taste and fewer reactions, which opens the door for use in new products such as hybrid milks with added ingredients. The fast-lactose hydrolysis process is further accelerated by salt addition, so the enzyme can be used in fresh cheese and related dairy applications. Additionally, its high-enzyme stability, relative dose reduction, and lactase addition flexibility during processing are significant advantages for milk and dairy product producers.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
